Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 10/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993995 | 0.84 | ADRA2B (0.56) | NOS1NOS2ADRA2BMCL1SLC6A4 | |
| SCHEMBL10100034 | 0.80 | ADRA2B (0.40) | ADRA2BMAPTTAAR1PRKCIACHE | |
| SCHEMBL15697702 | 0.79 | PARP1 (0.42) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL3127209 | 0.79 | SLC6A4 (0.54) | MCL1SLC6A4KCNH2SLC6A2HTR2A | |
| SCHEMBL1708812 | 0.79 | MAPT (0.39) | MCL1SLC6A4KCNH2SLC6A2HTR2A | |
| SCHEMBL10061642 | 0.78 | ALDH1A1 (0.48) | SLC6A4KCNH2HTR2AGAAMAPT | |
| SCHEMBL18588940 | 0.78 | SLC6A4 (0.55) | SLC6A4KCNH2SLC6A2HTR2A | |
| SCHEMBL14290420 | 0.78 | SLC6A4 (0.45) | NOS1NOS2MCL1SLC6A4KCNH2 | |
| SCHEMBL14418225 | 0.77 | SLC6A4 (0.40) | SLC6A4SLC6A2GAAMAPTTSHR | |
| SCHEMBL1467075 | 0.77 | PRKCI (0.42) | ADRA2BGAAMAPTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917195-B9 | SPLICEOSTATIN ANALOGS | PFIZER (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9764040-B2 | Spliceostatin analogs and methods for their preparation | PFIZER INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170014523-A1 | SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION | PFIZER (US) | 2017-01-19 | — | — | US | disclosed |
| US-9504669-B2 | Spliceostatin analogs and methods for their preparation | PFIZER INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160022626-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER (US) | 2016-01-28 | — | — | US | disclosed |
| US-9169264-B2 | Spliceostatin analogs and methods for their preparation | PFIZER INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2586778-A2 | Pyridazinone derivatives useful as glucan synthase inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022626-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | NOS1 4521/4885NOS2 4615/4885ADRA2B 3809/4885 |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | NOS1 4521/4885NOS2 4615/4885ADRA2B 3809/4885 |
| US-20170014523-A1 | SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION | SF3B5, SF3B1, SNRPA1 | NOS1 3080/4885NOS2 3386/4885ADRA2B 3917/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | NOS1 793/4885NOS2 1520/4885ADRA2B 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.